Since 1971, FDA and DEA have regulated the manufacture, importation, possession, use, and distribution of particular substances under the Controlled Substances Act. These agencies work in concert on protocols, recommendations, and information-sharing relating to schedules I through V substances. Currently, FDA and DEA’s joint initiatives seek to ensure product safety while balancing patient access through controlled substances and prescription monitoring programs. Panelists will examine the jurisdictional overlap between these agencies and impacts on the supply chain. Speakers will also discuss joint-agency efforts to combat the escalating opioid public health emergency, drug contamination issues and proposed rules for permanent telemedicine flexibilities to mitigate overprescribing and drug abuses.